Obeticholic acid (OCA, 6-ECDCA), an orally active synthetic FXR agonist, is currently in clinical trials for the treatment of NAFLD and cholestatic liver disease37, 38, 39. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.